Table 1.
Characteristics of included studies
| First author of study (reference No) | Number of patients | Gender (male:female) | Age (years) | Duration of disease (years) | QOL outcomes assessed | Included comparison with control | Longitudinal changes in QOL | Relationship of QOL with disease activity | Single/ Multicenter |
|---|---|---|---|---|---|---|---|---|---|
| Abularrage 2008 [37] | 158 TAK | 14:144 | 42.2 ± 1.1a | 11.7b | SF-36 | Yes (DC) | No | No | Multi |
| Akar 2008 [38] | 51 TAK, 75 HC | 10:41 TAK, 22:53 HC | 38.4 ± 13.5 aTAK, 38.8 + 10.9a HC | 7.6 ± 7.5a | SF-36, NHP | Yes (HC, DC) | No | Yes | Multi |
| Quartuccio 2012 [39] | 10 TAK | NA | NA | NAd | SF-36, EQ-5D | Yes (HC, DC) | Yes | No | Multi |
| Alibaz-Oner 2013 [40] | 55 TAK, 40 HC | 6: 49 TAK, 9: 31 HC | 42.3 ± 12.4a TAK, 41 ± 10.8a HC | 4.7 ± 6.5 | SF-36, HADS, HAQ, FM | Yes (HC) | Yes | No | Single |
| Grayson 2013 [41] | 57 TAK | 3:54 | 49.4 + 34.1a | 9.5 ± 14.8a | IPQ-R, MFI-20 | Yes (DC) | No | No | Multi |
| Yilmaz 2013 [42] | 165 TAK, 109 HC | 12: 153 TAK, 10:99 HC | 41.3 + 12.1a TAK, 40.4 ± 10.3a HC | 8.7 + 7.7a | SF-36, HADS, HAQ | Yes (HC) | No | Yes | Multi |
| Sreih 2016 [43] | 207 TAK | 6: 201 | 38.7 + 12.9a | NA | SF-36 | No | Yes | Yes | Multi |
| Gunsay 2017 [44] | 68 TAK | 8:60 | 42.9b | NA | SF-36 | No | No | No | Multi |
| Oliveira 2017 [45] | 6 TAK | 0:6 | 35.3 + 6.6a | 11.3 + 5.9a | SF-36, HAQ | No | Yes | No | Single |
| Omma 2017 [46] | 165 TAK, 51 HC | 19:146 TAK, 6:45 HC | 32.5 + 11.7a TAK, 38.2 ± 7.9a HC | 6 ± 5.4a | SF-36 | Yes (HC) | No | Yes | Multi |
| Chen 2018 [47] | 14 TAK | NA | NA | NA | EQ-5D | No | Yes | No | Single |
| Sreih 2018 [48] | 31 TAK | NA | NA | NA | Qualitative study | No | No | No | Multi |
| Campochiaro 2020 [49] | 23 TAK | 2:21 | 43.8 + 14.4a | 8.0 ± 5.1a | HAQ | No | Yes | No | Single |
| Garen 2020 [50] | 33 TAK | 0:33 TAK | 32c TAK | 8.9c | SF-36 | Yes (HC) | No | No | Single |
| Luna-Vargas 2020 [51] | 15 TAK | 0:15 | 38.7 ± 11.1a | 10 ± 8.8a | SF-36, HAQ, MFI | No | No | No | Single |
| Nakaoka 2020 [52] | 36 TAK | 5:31 TAK | 30.9 ± 15.5a TAK | 5.0 ± 6.0a | SF-36 | Yes (HC) | Yes | No | Multi |
| Rimland 2020 [53] | 56 TAK | 11:45 | 33.4 ± 15.9a | 7.4 ± 10.1a | SF-36, BIPQ, MFI | Yes (DC) | No | Yes | Single |
| Schwartz 2020 [54] | 47 TAK | 7:40 | 34 ± 14a | NA | BIPQ | Yes (DC) | Yes | No | Single |
| Astley 2021 [55] | 17 TAK, 17 HC | 6:11 TAK, 6:11 HC | 18.4 ± 3.4a TAK, 18.5 + 3.5b HC | 9.5 + 4.2a | SF-36 | Yes (HC) | No | No | Multi |
| dos Santos 2021 [56] | 20 TAK, 16 HC | 0:20 TAK, 0:16 HC | 41.9 ± 6.2a TAK | 15.2 ± 7.8a | SF-36, HAQ, IPAQ-SF, WIQ | Yes (HC) | No | No | Multi |
| Erdal 2021 [57] | 77 TAK | 7:70 | 44 ± 9.3a | 7 ± 3.7a | IPQ-R, HADS, WPAI | No | No | Yes | Single |
BIPQ Brief Illness Perception Questionnaire, DC Disease controls, EQ-5D EuroQol 5 dimensions, FM Fibromyalgia, HADS Hospital Anxiety and Depression Scale, HAQ Health Assessment Questionnaire, HC healthy controls, IPAQ-SF International Physical Activity Questionnaire – Short Form, IPQ-R Illness Perception Questionnaire, MFI Multidimensional fatigue inventory, NA Not available, NHP Nottingham Health Profile, QOL quality of life, SF-36 36 item Short Form Survey, TAK Takayasu arteritis, WIQ Walking Impairment Questionnaire, WPAI Work Productivity and Activity Impairment Questionnaire
aMean (standard deviation [SD])
bMean
cMedian
dMean disease duration (± SD) for entire cohort of 15 patients at baseline was 3.2 ± 2.5 years (not separately mentioned for the ten patients for whom SF-36 and EQ-5D were reported)